Antimicrobial Resistance (AMR)

As the leading global provider of generic antibiotics, Sandoz is committed to improving global access to medicine. Our parent company Novartis, one of 130 companies to sign the ‘Davos Declaration’ in January 2016 calling for a collective response to AMR, is also one of 13 companies to sign the subsequent ‘Industry Roadmap’ in September 2016, outlining concrete actions across four areas: access, responsible use, responsible manufacturing and R&D.

We’re equally committed to ensuring the responsible use of medicine. This may mean making some tough business choices as we balance short and long term interests, but we are not alone. Let’s be clear: AMR is a truly global problem, which requires global, multi-stakeholder collaboration.

There are no simple, quick-fix solutions. But with rising political attention and a pledge from industry to play a meaningful role, we have a unique window of opportunity to take concrete steps to combat this growing global threat. Let’s do the right thing, together.

Antimicrobial Resistance (AMR)

Latest News:

Thought Leadership:

Multimedia:

Related Links